Vascular Effects of Glucagon-like peptide 1 Receptor Agonist (Liraglutide) on an Animal Model of Type 1 Diabetes
Year: 2017
Type: dissertation
Abstract: Glucagon-like peptide 1 (GLP-1) is a crucial hormone that binds to its receptor (GLP-1R) and plays several beneficial roles, being is main function potentiating insulin secretion inpancreatic β cells, induced by the entry of nutrients (''incretin effect''). Thus, GLP-1R agonists(GLP-1RAs) correspond to one of the main therapeutic targets for the treatment of DMT2,such as Liraglutide, since, in addition to insulin secretion, they also promote the increase ofproliferation and the decrease of the apoptotic rate of β cells of the islets of Langerhans, andexhibit positive actions in the cardiovascular system.DMT1 occurs when the pancreas is completely unable to produce insulin or producesin low quantity, due to the total or partial absence of β cells, respectively, contributing to themaintenance of the chronic hyperglycemic state, which has as consequence several side effects,mainly endothelial dysfunction and consequently the onset of cardiovascular diseases.Therefore, the application of GLP-1RAs to DMT1 therapy, combined with insulin, is suggestedbecause of its possible beneficial effects at cardiovascular level.The main objective of this study was to evaluate the effects of Liraglutide (Victoza®) onthe cardiovascular system and how this effect is altered in the presence of DMT1.For this, DMT1 was induced with Streptozotocin (STZ) in male Wistar rats at 12 weeksof age, by single intraperitoneal injection (65 mg/kg in 10 mM citrate buffer, pH 4.5). At 14weeks, the animals were divided into four groups: two control groups, one group subject totreatment with Liraglutide (200 μg/kg x 2/day) and one not, and two diabetic groups underthe same conditions as the control groups. After 2 weeks of treatment, the animals weresacrificed for the realization of functional and biochemical studies.In the in vivo studies, the ACh induced a relaxation that was practically abolished by thepresence of NG-Nitro-L-Arginine Methyl Ester (L-NAME), verifying that the endothelium wasfunctional and the relaxation was NO-dependent. In addition, it was also demonstrated thatLiraglutide affected the vasodilatory response of ACh.For the pharmacological characterization of Liraglutide, concentration-response curveswere performed in the presence of the drug, with pre-incubation with L-NAME, Exendin-3(Ex-3) and insulin. Liraglutide was found to have a NO-independent contractile action verifiedby the non-altered response in the presence of L-NAME; this action is partially mediated byGLP-1R, since the presence of Ex-3 in the control group led to a decrease in the contractileresponse of the drug, however in the diabetic group the same was not verified. The presence of insulin leads to a decreased of the potency of the Liraglutide-induced contraction, whereasin the diabetic group the presence of insulin showed a tendency to increase the maximumLiraglutide contraction. Finally, the effect of Liraglutide and insulin was evaluated individually,with the two drugs inducing contraction, which is higher in diabetic animals.To study the mechanisms underlying the results obtained by the functional studies,biochemical studies were performed, such as the Western Blotting technique that allowed todo the quantification of GLP-1R, eNOSp / eNOS and insulin receptor (IRp/IRβ) density. GLP-1R was shown to be decreased in the non-treated diabetic group, however, in diabetic animalstreated with Liraglutide, the density was increased with a statistically significant difference (P<0.05), compared to the first group. Regarding to eNOS and its phosphorylated form, nostatistically significant differences were observed between the groups; however, the controlgroup treated with Liraglutide has demonstrated a tendency to increase the active form of theprotein. Concerning to the quantification of the IR density, both forms of the receptor aredecreased in the presence of the disorder, and treatment with Liraglutide in the control grouphas shown a tendency for impairment of the active form of the receptor.Analyzing histochemistry, there was possible to notice some changes in the aortictissue in the diabetic group, since they presented matrix alterations and tissue disorganization.Relatively to GLP-1R immunohistochemistry, it was verified that there was a heterogeneousdistribution within each group and a decrease of labeling in diabetic animals relative to controlanimals.Based on this study, we conclude that both drugs induce cardiovascular contraction,with Liraglutide contraction being NO-independent and partially mediated by its binding tothe receptor (GLP-1R). Thus, a combination therapy of insulin and Liraglutide may be beneficialin the treatment of early-stage DMT1, but possibly not in patients with a known cardiovascularhistory.
Language: Portuguese
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7224030646
